GLP-1 Obesity Drugs Suppress Movement, Threatening Muscle During Weight Loss

A large real-world study using NIH All of Us and Fitbit data finds adults starting GLP-1 obesity medications reduce daily steps (5,047→4,487) and MVPA (28→22 minutes), contradicting the assumption that weight loss boosts activity. The decline risks lean muscle loss during rapid weight loss, underscoring the need to pair GLP-1 treatments with structured exercise and resistance training from the start. The analysis, drawn from 1,950 adults with 753 wearing-device users, shows the biggest drops in men and those with joint/muscle pain, while age or cardiovascular history did not shield against the trend; researchers call for integrated behavioral interventions and remote monitoring.